Articles from iXCells Biotechnologies USA, Inc.

Mosaic Neuroscience and iXCells Biotechnologies USA, Inc. (“iXCells”) today announced a groundbreaking pilot project aimed at making it easier to develop precision drugs for ALS, a notoriously complex and deadly disease.

iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform.

iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company providing innovative cell products and preclinical drug development services to the global academic, biotech, pharmaceutical, and rare disease communities today announced the grand opening celebration of its new San Diego headquarters and Rare Disease Month Workshop.

iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company specializing in providing cell-based products and drug discovery service solutions to the global academic, biotech, pharmaceutical, and rare disease communities, today announced the appointment of Helge Bastian, PhD, as the company’s new Chief Executive Officer.

iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company specializing in providing cell-based products and drug discovery solutions to the global academic, biotech and pharmaceutical communities, today announced completing key growth initiatives.